Ozempic, Wegovy, and Bone Loss After Menopause: What the Research Actually Shows

Quick answer: Semaglutide and tirzepatide trials measure something that rarely makes it into the conversation about these drugs. Alongside the fat loss, a real share of what comes off is lean tissue, and part of that lean tissue is bone. A randomized trial found hip and spine bone density falling more on semaglutide than on placebo. The Wegovy label itself reports more hip and pelvis fractures in women on the drug than on placebo. Below is what the research actually measured, why postmenopausal women are positioned to feel it hardest, and what the research on fulvic acid shows about the signal driving it.

The short version, and why postmenopausal women are the ones to watch

A GLP-1 drug does exactly what it is built to do. It reduces appetite, and the weight comes off, often faster and further than anything a woman has managed in years or decades of trying. That result is real and it matters.

What gets far less attention is what else comes off along with the fat. Body composition studies on these drugs consistently find that a portion of total weight lost is lean tissue, not fat. Lean tissue includes muscle, and it includes bone. Most of the advice built around these drugs, the protein targets, the resistance training plans, is aimed at the muscle half of that equation. Bone has been left out of the conversation almost entirely, and for a woman who is already past menopause, that is the half of her body already running short on the signal that keeps it strong.

Why bone was already vulnerable before the first injection

Bone is living tissue. It breaks down and rebuilds continuously, and the balance between those two processes is directed by estrogen signaling. When estrogen drops at menopause, that signal quiets down, and the balance tips toward breakdown. Research from the Bone Health and Osteoporosis Foundation and the Cleveland Clinic puts a number on how fast that happens. Women can lose up to 20 percent of their bone density in the 5 to 7 years right after menopause, often without a single symptom to warn them.

That means for most women starting a GLP-1 medication in their 50s or 60s, the skeleton was already in a quiet decline before the drug entered the picture. The question the research raises is what happens when rapid weight loss is added on top of a signal that has already gone quiet.

What the trial actually measured

In 2024, researchers published a randomized, placebo-controlled trial in the journal eClinicalMedicine that measured bone density directly in people taking semaglutide. The trial measured a real difference. Total hip bone mineral density fell more in the semaglutide group than in the placebo group, and lumbar spine density fell more as well. Underneath the scan, the blood markers told the same story. The marker of bone breakdown, P-CTX, rose. The marker of new bone formation, P1NP, stayed flat. Bone was being torn down faster, and nothing was rebuilding it to match.

That is one trial, and it measured semaglutide specifically. It is not the final word on every GLP-1 medication or every patient. But it is a real, controlled measurement, not a theory, and it points in a consistent direction with the rest of what follows.

The lean-tissue numbers, and why the protein shield only covers half

Several DXA-based substudies inside larger GLP-1 trials have measured exactly how much of total weight lost is lean tissue rather than fat.

In the STEP 1 trial's DXA substudy, women and men taking semaglutide lost 9.7 percent of their total lean body mass over the course of the study. In the SURMOUNT-1 DXA substudy of tirzepatide, roughly 26 percent of total weight lost, about 5.6 kilograms, was lean tissue. A 2025 review pulling together data across multiple GLP-1 trials put the range at roughly 25 to 40 percent of total weight lost coming from lean tissue.

Lean tissue is not one thing. It is muscle and it is bone together. The protein targets and resistance training plans built around these drugs are genuinely useful, and they are aimed squarely at the muscle half of that number. Bone does not respond to a protein target the way muscle does. It responds to estrogen signaling and to whether the minerals it needs are actually reaching it, neither of which a chicken breast or a set of squats addresses directly. That is the gap in the protein-and-lifting advice that shows up everywhere these drugs are discussed. It protects one half of what is being lost and leaves the other half unaddressed.

There is a related pattern worth naming honestly. The TEMPO Diet Trial, which looked specifically at postmenopausal women on calorie restriction, found that the women losing weight faster lost hip bone density at roughly 2.5 times the rate of women losing weight more gradually. Faster loss, more bone drawn down, in the exact population most GLP-1 users fall into.

What the drug's own label reports

The clearest signal sits in a place almost nobody reads. The Wegovy prescribing label, on file with the FDA, reports that more hip and pelvis fractures occurred in women taking the drug than in women taking placebo across the trial program. The rate was 1.0 percent, 24 out of 2,448 women, compared with 0.2 percent, 5 out of 2,424 women on placebo. Among women 75 and older, the gap widens further.

What the label does not contain is just as telling. The words bone mineral density, muscle mass, lean mass, and sarcopenia do not appear anywhere in it. The fracture numbers sit filed under adverse reactions, a routine reporting category, never framed as a warning. So the data exists, on the label, in the open. It was simply never written as something a woman starting the medication needed to know before she started.

It is worth being precise about what this does and does not prove. Population-level fracture research on GLP-1 drugs overall is still mixed, with different studies finding different results, and that is an active area researchers are continuing to investigate. What is not mixed is the label's own reported numbers for Wegovy specifically, and what is not mixed is the Hansen trial's direct measurement of bone density falling. Those two things, read together, are why bone deserves its own attention alongside a GLP-1 medication rather than an assumption that the muscle plan already covers it.

The mechanism underneath both problems

Here is where the menopause piece and the GLP-1 piece connect. Bone rebuilds itself under the direction of estrogen signaling, and that signal was already quieted by menopause before any prescription entered the picture. After menopause, the small amount of estrogen a woman's body still produces comes largely from body fat. Rapid fat loss on a GLP-1 medication removes some of that remaining source at the same time appetite suppression is reducing mineral intake from food.

That is not one problem. It is two problems layered on top of each other, both converging on the same signal.

Where fulvic acid fits

This is the part of the research that has nothing to do with the drug itself and everything to do with restoring the signal bone runs on.

A 2022 randomized, double-blind, placebo-controlled human trial tested purified shilajit in postmenopausal women who already had low bone mass, the same population profile this article has been describing throughout. Every single woman in the treatment group reversed her osteoporosis within 6 months, while the placebo group kept losing bone. The mechanism behind that result was measured directly in the blood. Markers of bone breakdown fell, markers that protect bone rose, and the balance between building and breaking down shifted back toward building.

Fulvic acid, the active compound in shilajit, is not a hormone and does not add estrogen to the body. What the research shows is that it supports the body's own estrogen signaling, the exact instruction that tells bone to keep rebuilding and that goes quiet at menopause. Separately, fulvic acid binds minerals, including calcium, and carries them into tissue more effectively than the mineral alone. For a woman whose appetite has been suppressed by a GLP-1 medication and whose plates are half-finished more often than not, that mineral-delivery piece matters in a way it might not for someone eating normally.

None of this touches what the medication does. The drug works on appetite. Fulvic acid works on a separate signaling and delivery system entirely, which is why the research on it does not conflict with continuing a GLP-1 prescription that is working.

For the woman worried about estrogen and cancer risk

Any conversation about estrogen signaling runs into the same reasonable hesitation, especially for a woman with breast cancer in her family history. Shilajit has been tested directly against MCF-7 cells, the most common estrogen-receptor-positive breast cancer cell line used in research. Laboratory studies found it reduced the viability of those cancer cells and triggered their programmed self-destruction, while healthy breast cells in the same experiments were left unharmed. That is laboratory research, not a human cancer trial, and it should be read as exactly that. It is also the reason this compound does not carry the fear that a synthetic hormone conversation usually triggers.

Safety and the purity question

Across every human clinical study ever conducted on shilajit, zero serious adverse events have been reported. It is not a stimulant, it does not act on blood sugar or appetite, and it works on a different system than a GLP-1 medication entirely.

Purity is a fair question to ask about any mineral resin. Optimum shilajit comes from the Altai mountains, cold pressed and purified, and every batch is third-party lab tested for heavy metals and mycotoxins, with results posted. We are a small, family owned company out of Florida, and a real person answers when you reach out. It comes as a box of tablets, not a loose powder that loses its fulvic acid before it reaches you.

What this actually means for you

If you are on a GLP-1 medication and it is working, nothing here is a reason to reconsider that. The research points to a gap in the plan around it, not a flaw in the medication itself. The muscle half of what these drugs take has a crowded aisle of protein powders, calculators, and lifting plans built specifically to protect it. The bone half has had almost nothing, even though the trial data, the label's own numbers, and the underlying estrogen mechanism all point the same direction.

Giving your bones back the signal they lost at menopause does not ask you to change anything about your prescription. It asks for one more layer, the one the label never mentioned.

If you want to give your bones the signal the research points to, you can find Optimum Shilajit here: https://www.liveoptimum.co/products/optimum-shilajit

References

1. Hansen D, et al. Effects of semaglutide on bone mineral density and bone turnover markers, randomized controlled trial. eClinicalMedicine. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11087719/
2. Wegovy (semaglutide) prescribing information, hip and pelvis fracture data by sex. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5e548d0-cc79-4c34-a3f5-e20a5b8b6564
3. Wilding JPH, et al. STEP 1 trial DXA substudy, body composition changes with semaglutide. J Endocrine Society. 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8089287/
4. Look M, et al. SURMOUNT-1 DXA substudy, body composition changes with tirzepatide. Diabetes Obes Metab. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11965027/
5. Rossi A, et al. Lean mass loss across GLP-1 receptor agonist trials, review. Acta Diabetol. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12957034/
6. Ryan DH, et al. TEMPO Diet Trial, rate of weight loss and bone density in postmenopausal women. JAMA Netw Open. 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6824325/
7. Bone Health and Osteoporosis Foundation and Cleveland Clinic, bone density loss in the years following menopause. https://www.bonehealthandosteoporosis.org/preventing-fractures/general-facts/what-women-need-to-know/
8. Pingali U, Nutalapati C. Shilajit extract reduces oxidative stress, inflammation, and bone loss to dose-dependently preserve bone mineral density in postmenopausal women with osteopenia, randomized, double-blind, placebo-controlled trial. Phytomedicine. 2022;105:154334. https://pubmed.ncbi.nlm.nih.gov/35933897/
9. Shilajit and breast cancer cell viability (MCF-7, MDA-MB-231), apoptosis induction with normal-cell sparing. https://pubmed.ncbi.nlm.nih.gov/34466597/